3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumors
1
Interventions
Paclitaxel
12
atezolizumab
11
Gemcitabine
9
pembrolizumab
8
Injections
6
Carboplatin
6
Irinotecan
5
Docetaxel
5
Cetuximab
5
tocilizumab
4
navitoclax
4
Leucovorin
4
Fluorouracil
4
Bevacizumab
4
olaparib
3
cobimetinib
3
Oxaliplatin
3
Nivolumab
3
zolbetuximab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
tivozanib
2
tislelizumab
2
spartalizumab
2
ridaforolimus
2
plocabulin
2
obinutuzumab
2
motesanib diphosphate
2
liposomal doxorubicin
2
linifanib
2
lenvatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Solid Tumors
×
ODM-207
×
Clear all
NCT03035591
2019-10-15
BETIDES
Orion Corporation, Orion Pharma
Phase 1/2
Completed
36 enrolled